Clinical trials: MCD
Lymphoproliferative Disorder, HHV-8
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
This study will gain information about a rare disorder called KSHV-associated multicentric Castleman's disease (MCD). KSHV, a virus, causes several kinds of cancer, including some forms of MCD.
- Conditions
- Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
- Trial name
- NCT00092222
- Testing
- Etoposide, Interferon-alpha, Rituximab
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Prospective Longitudinal Breast Cancer Study
The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.
- Trial name
- NCT02270931
- Testing
- CA 15-3 Assay
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Fujirebio Diagnostics, Inc.
Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis
- Trial name
- NCT07499700
- Testing
- BAT4406F
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Bio-Thera Solutions
Diffuse Large B-Cell Lymphoma (DLBCL)
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
This is a prospective, open-label, single-arm, single-center, Phase II clinical study designed to evaluate the efficacy and safety of Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab…
- Trial name
- Pola-ZRCHP (NCT07608978)
- Testing
- POLA-R-CHP+Zanubrutinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Castleman Disease, Castleman's Disease
Castleman Disease Collaborative Network Biobank
The purpose of this study is to create a biobank, which collects, stores, and distributes samples of human tissues, blood, and related health information to qualified scientists, in order to help doctors and researchers better…
- Conditions
- Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia
- Trial name
- "Castlebank" (NCT02871050)
- Testing
- Sample Collection
- Where
- United States
- Sponsor
- Castleman Disease Collaborative Network
Lymphoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for non-Hodgkin's lymphoma.
- Trial name
- NCT00006250
- Testing
- chlorambucil, dexamethasone, fludarabine phosphate
- Where
- 59 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Lymphoma Trials Office
Multicentric Castleman Disease
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
The purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial.
- Trial name
- NCT04585893
- Testing
- Rituximab, Etoposide
- Where
- Malawi
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
This protocol is designed to evaluate the side effects of rV-DF3/MUC1 and to determine the safest dose which should be used in the treatment of breast cancer.
- Trial name
- NCT00003761
- Testing
- rV-DF3/MUC1
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Gastric Cancer
Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.
In this study, safety and effects of MUC1-gene-DC-CTL and MUC1-peptide-DC-CTL on human gastric cancer are going to be investigated.
- Trial name
- NCT02602249
- Testing
- MUC1-gene-DC-CTL, MUC1-peptide-DC-CTL
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Beijing Doing Biomedical Co., Ltd.
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis
NEPTUNE Match Study
NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.
- Conditions
- Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome
- Trial name
- NEPTUNE Match (NCT04571658)
- Testing
- Communication
- Where
- 16 sites in United States
- Volunteers
- 375 people
- Sponsor
- University of Michigan
Glomerulonephritis
A Study of Rituximab in Frontline Therapy for Glomerulonephritis
This study included patients with glomerulonephritis who planned to receive rituximab treatment, and observed the efficacy and safety of rituximab in different glomerulonephritis in the real world.
- Trial name
- NCT05761938
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Breast Cancer, Anthropometric Measurements
2D:4D Finger Ratio and Breast Cancer in Women
This prospective study aims to evaluate the 2D:4D finger ratio in women diagnosed with breast cancer compared to healthy controls and to examine its potential association with tumor markers, including carcinoembryonic antigen…
- Conditions
- Breast Cancer, Anthropometric Measurements, Females
- Trial name
- NCT07436169
- Where
- Turkey (Türkiye)
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Malatya Turgut Ozal University
Castleman Disease, Angiofollicular Lymphoid Hyperplasia
Unlock the Cell: Castleman's Disease Flow Cytometry Study
Castleman disease, a rare lymphoproliferative disorder, is characterized by inflammatory cytokine production and multiple organ system dysfunction.
- Conditions
- Castleman Disease, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia
- Trial name
- NCT02853968
- Testing
- Blood draw/buccal swab
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Castleman Disease, Castleman's Disease, Multicentric
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
- Trial name
- NCT03933904
- Testing
- Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania
Interstitial Lung Disease, Cardiovascular Morbidity
Interstitial Lung Disease is a Risk Factor for Cardiovascular Disease
A group of Interstitial pulmonary fibrosis will be recruited from Assiut university hospital outpatient clinic. Evaluation will be done regarding cardiovascular comorbidities (Cardiovascular comorbidities will be evaluated with…
- Trial name
- NCT06539962
- Testing
- Krebs von den Lungen-6 (KL-6)
- Where
- Egypt
- Volunteers
- 134 people
- Sponsor
- Assiut University
Castleman Disease, Castleman's Disease
International Registry for Patients With Castleman Disease
The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.
- Conditions
- Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia
- Trial name
- ACCELERATE (NCT02817997)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania